RxDoctor Payments Data

Bradley Miller, MD

Critical Care Medicine · San Antonio, TXNPI 1144499344

Payments from drug & device makers

$3,030in general payments, 2019–2025

Across 171 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Boehringer Ingelheim$279
  • Actelion Pharmaceuticals US, Inc.$277
  • AstraZeneca$271
  • AbbVie$174
  • Johnson & Johnson$169
  • plus $844 from 17 others

What the payments were for

  • Food & beverage$3,030100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,030 in reported general payments places this provider in the 75th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$221,467
Medicare patients
529
Services billed
3,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate37$482,842
Dupixent PenDupilumab68$285,873
Trelegy ElliptaFluticasone/Umeclidin/Vilanter219$199,330
Breo ElliptaFluticasone/Vilanterol89$50,664
NucalaMepolizumab12$45,148
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$32,767
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$31,259
SymbicortBudesonide/Formoterol Fumarate58$20,439
Advair HfaFluticasone Propion/Salmeterol20$9,394
Spiriva RespimatTiotropium Bromide17$9,355
Arnuity ElliptaFluticasone Furoate19$8,674
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$8,245
DuleraMometasone/Formoterol19$6,880
EliquisApixaban12$6,637
Albuterol Sulfate HfaAlbuterol Sulfate251$6,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$279$492,19754 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta$1,014$335,074382 claims
AstraZenecaBreztri Aerosphere, Symbicort$271$53,20697 claims
MerckDulera$31$6,88019 claims
PfizerEliquis$14$6,63712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →